ArticlePatient preference and adherence2017
Evaluating the patient experience after implantation of a 0.4 mg sustained release dexamethasone intracanalicular insert (Dextenza™): results of a qualitative survey.
Article in Patient preference and adherence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04371445 (Intracanalicular Dexamethasone Insert for Management of Post-operative Pain and Inflammation in Patients Undergoing Vitreoretinal Surgery), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intracanalicular Dexamethasone Insert for Management of Post-operative Pain and Inflammation in Patients Undergoing Vitreoretinal Surgery
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Dose-selection study of clobetasol propionate ophthalmic suspension that evaluated inflammation and pain after cataract surgery.Journal of cataract and refractive surgery · 2026Trial
- A Randomized, Controlled, Prospective Study of the Effectiveness and Safety of an Intracanalicular Dexamethasone Ophthalmic Insert (0.4 Mg) for the Treatment of Post-Operative Inflammation in Patients Undergoing Refractive Lens Exchange (RLE).Clinical ophthalmology (Auckland, N.Z.) · 2021Trial
- Safety and Comfort of an Innovative Drug Delivery Device in Healthy Subjects.Translational vision science & technology · 2020Trial
- Dropless after cataract surgery (DACS): concepts, evidence and clinical potential.Eye (London, England) · 2026Review
- Postoperative Inflammation and Pain Management with Intracanalicular Dexamethasone Insert: Real-World Applications.Ophthalmology and therapy · 2026Review
- Dropless cataract surgery: comparing sub-Tenon's and topical steroids for postoperative inflammation prophylaxis.Eye (London, England) · 2026Article
- Subconjunctival Triamcinolone Acetonide Injection Compared with Dexamethasone Ophthalmic Insert for Inflammation Prophylaxis After Cataract Surgery: A Comparative Clinical Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Management of Post-Operative Inflammation After Cataract Surgery with Intracanalicular Dexamethasone Implant and Topical Ketorolac.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Drug Delivery Systems for Glaucoma: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Efficacy and Safety of Dexamethasone Intracanalicular Insert Use in Patients with Chronic Seasonal/Perennial Allergic Conjunctivitis: A Systematic Review and Meta-Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Progress in Ocular Drug Delivery: Challenges and Constraints.Handbook of experimental pharmacology · 2024Article
- Early Real-World Patient and Staff Experience with an Intracanalicular Dexamethasone Insert.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Design and Development of Antibacterial/Anti-inflammatory Dual Drug-Loaded Nanofibrous Inserts for Ophthalmic Sustained Delivery of Gentamicin and Methylprednisolone:Advanced pharmaceutical bulletin · 2022Article
- Prospective, Randomized, Fellow Eye-Controlled Study of Postoperative Pain and Inflammation Control with an Intracanalicular Dexamethasone 0.4 mg Ophthalmic Insert Following Small Incision Lenticule Extraction.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Thermal Pulsation with or without Dexamethasone Intracanalicular Insert for Meibomian Gland Dysfunction: A Prospective, Masked Trial.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- In Clinic Optometrist Insertion of Dextenza (Dexamethasone Ophthalmic Insert 0.4mg) Prior to Cataract Surgery: The PREPARE Study.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Sustained-release drug delivery systems for the treatment of glaucoma.International journal of ophthalmology · 2021Review
- Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Same-Day versus Next-Day Dexamethasone Intracanalicular Insert Administration for Inflammation and Pain Control Following Cataract Surgery: A Retrospective Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Plasma Pharmacokinetic Parameters of Dexamethasone Following Administration of a Dexamethasone Intracanalicular Insert in Healthy Adults.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study is to evaluate the patient experience of sustained release dexamethasone intracanalicular insert (Dextenza™) following cataract surgery as part of a Phase III clinical trial program.
methodsThis cross-sectional, qualitative evaluation involved individual interviews lasting approximately 45 minutes. Patients from four US investigational study sites who had previously received an insert were enrolled. There were no predesignated end points; this was a qualitative survey seeking a deeper understanding of patient experience.
resultsTwenty-five patients were interviewed. Most patients (92%) reported the highest level of satisfaction grade with regard to overall product satisfaction. All patients described the insert as comfortable. Most patients (96%) described their overall experience with the insert as very convenient or extremely convenient. Twenty-two of 23 (96%) participants rated their experience with the insert as "very" or "extremely convenient", compared to previous topical therapy, and 88% of patients stated that if they were to undergo cataract surgery again, they would request the insert. When asked if they would recommend the insert to family members or friends, 92% stated they would. The survey found that 84% of participants would be willing to pay more for the insert than for eye drop therapy.
conclusionThe dexamethasone insert was found by patients to be highly favorable with regard to overall satisfaction, convenience, and comfort. The insert was well received and largely preferred over topical therapy alternatives following surgery. More extensive evaluation of the patient experience is warranted, and future studies should help inform design of the next generation of sustained release drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.